IPSEN, OOO
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumor
- Interventions
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 43
- Registration Number
- NCT04852679
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Sciences, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines
- Conditions
- Moderate to Severe Upper Facial Lines
- Interventions
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 727
- Registration Number
- NCT04821089
- Locations
- 🇫🇷
MEDITI - Clinique Del Mar, Antibes, France
🇫🇷Palais de Flore, Lyon, France
🇫🇷Clinique de Chirurgie Esthétique Iéna, Paris, France
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.
- Conditions
- Spasticity
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 240
- Registration Number
- NCT04752774
- Locations
- 🇺🇸
Rancho Los Amigos National Rehab, Downey, California, United States
🇺🇸Kansas Institute of Research, Overland Park, Kansas, United States
🇺🇸Quest Research Institute, Farmington Hills, Michigan, United States
Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 32
- Registration Number
- NCT04736602
- Locations
- 🇨🇳
Chengdu Women's and Children's Central Hospital, Chengdu, China
🇨🇳Jiangxi Provincial Children's Hospital, Nanchang, China
🇨🇳Children's Hospital of Nanjing, Nanjing, China
Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines.
- Conditions
- Moderate Upper Facial LinesSevere Upper Facial Lines
- Interventions
- Biological: IPN59011Drug: PlaceboBiological: Azzalure
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 56
- Registration Number
- NCT04736745
- Locations
- 🇩🇪
Clinical Research Centre (CRS), Berlin, Germany
An International Cross-sectional Survey to Evaluate the Burden of Fibrodysplasia Ossificans Progressiva (FOP) on Patients and Their Families.
- Conditions
- Fibrodysplasia Ossificans Progressiva
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2021-05-21
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 411
- Registration Number
- NCT04665323
- Locations
- 🇺🇸
Ipsen Central Contact, Cambridge, Massachusetts, United States
United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting
- Conditions
- Neuroendocrine Tumours (NET)
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 80
- Registration Number
- NCT04649580
- Locations
- 🇬🇧
University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
🇬🇧Cardiff and Vale University LHB, Cardiff, United Kingdom
🇬🇧University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom
Relation Between Dose and Time to Reinjection of Botulinum Toxin-A in Patient With Poststroke Spasticity From a Real-world Healthcare Insurance Database.
- Conditions
- Post Stroke Spasticity
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2020-12-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 451
- Registration Number
- NCT04649632
- Locations
- 🇳🇱
Ipsen Facility, Hoofddorp, Netherlands
Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 1540
- Registration Number
- NCT04637204
- Locations
- 🇬🇧
Ipsen Facility, Slough, United Kingdom
Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer.
- Conditions
- Colorectal CancerPancreatic Ductal Adenocarcinoma
- Interventions
- Drug: 111In-IPN01087 High doseDrug: 111In-IPN01087 Low dose
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- Ipsen
- Registration Number
- NCT04632199
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇧🇪UZ Leuven, Leuven, Belgium
🇫🇷Centre Léon Bérard, Léon, France